X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SUN PHARMA SUVEN LIFE/
SUN PHARMA
 
P/E (TTM) x 19.8 25.9 76.6% View Chart
P/BV x 3.7 3.8 97.2% View Chart
Dividend Yield % 1.0 0.6 167.6%  

Financials

 SUVEN LIFE   SUN PHARMA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
SUN PHARMA
Mar-17
SUVEN LIFE/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs339842 40.2%   
Low Rs144572 25.2%   
Sales per share (Unadj.) Rs39.2131.6 29.8%  
Earnings per share (Unadj.) Rs7.532.7 22.8%  
Cash flow per share (Unadj.) Rs8.838.0 23.1%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.80.5 167.4%  
Book value per share (Unadj.) Rs49.0152.7 32.1%  
Shares outstanding (eoy) m127.282,399.26 5.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.25.4 114.5%   
Avg P/E ratio x32.421.6 149.6%  
P/CF ratio (eoy) x27.518.6 147.7%  
Price / Book Value ratio x4.94.6 106.4%  
Dividend payout %26.810.7 250.4%   
Avg Mkt Cap Rs m30,7321,696,877 1.8%   
No. of employees `0001.017.5 5.4%   
Total wages/salary Rs m41649,023 0.8%   
Avg. sales/employee Rs Th5,236.118,028.3 29.0%   
Avg. wages/employee Rs Th436.52,798.8 15.6%   
Avg. net profit/employee Rs Th995.54,479.5 22.2%   
INCOME DATA
Net Sales Rs m4,995315,784 1.6%  
Other income Rs m1946,232 3.1%   
Total revenues Rs m5,189322,016 1.6%   
Gross profit Rs m1,233100,893 1.2%  
Depreciation Rs m16712,648 1.3%   
Interest Rs m543,998 1.4%   
Profit before tax Rs m1,20590,479 1.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m25512,116 2.1%   
Profit after tax Rs m95078,462 1.2%  
Gross profit margin %24.731.9 77.2%  
Effective tax rate %21.213.4 158.1%   
Net profit margin %19.024.8 76.5%  
BALANCE SHEET DATA
Current assets Rs m4,986329,537 1.5%   
Current liabilities Rs m1,042178,870 0.6%   
Net working cap to sales %79.047.7 165.5%  
Current ratio x4.81.8 259.7%  
Inventory Days Days6179 77.2%  
Debtors Days Days3983 47.0%  
Net fixed assets Rs m3,126204,766 1.5%   
Share capital Rs m1272,399 5.3%   
"Free" reserves Rs m3,717363,997 1.0%   
Net worth Rs m6,236366,397 1.7%   
Long term debt Rs m43214,361 3.0%   
Total assets Rs m8,079614,102 1.3%  
Interest coverage x23.223.6 98.3%   
Debt to equity ratio x0.10 176.9%  
Sales to assets ratio x0.60.5 120.2%   
Return on assets %12.413.4 92.5%  
Return on equity %15.221.4 71.1%  
Return on capital %18.924.8 76.0%  
Exports to sales %87.50-   
Imports to sales %12.20-   
Exports (fob) Rs m4,371NA-   
Imports (cif) Rs m611NA-   
Fx inflow Rs m4,66644,118 10.6%   
Fx outflow Rs m94224,484 3.8%   
Net fx Rs m3,72419,634 19.0%   
CASH FLOW
From Operations Rs m92270,822 1.3%  
From Investments Rs m-619-42,216 1.5%  
From Financial Activity Rs m-698-22,854 3.1%  
Net Cashflow Rs m-3966,107 -6.5%  

Share Holding

Indian Promoters % 63.4 63.7 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.1 -  
FIIs % 0.0 23.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 8.3 439.8%  
Shareholders   37,287 133,026 28.0%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 16, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUVEN LIFE 8-QTR ANALYSIS

COMPARE SUVEN LIFE WITH

MARKET STATS